Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting

NCT01394029•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients treated with deferasirox for transfusional hemosiderosis according to the local prescribing information.
•(the patients are either beginning treatment with deferasirox at the time of enrollment in the sentinel site monitoring or are currently under treatment with deferasirox and have started the treatment under prescription up to twelve months prior to enrollment in the sentinal site monitoring.

Exclusion Criteria

•Patients with non-transfusional hemosiderosis
•Patients treated with deferasirox in an interventional clinical trial

Locations (10)

Novartis Investigative Site

Cairo, Cairo Governorate, Egypt

Novartis Investigative Site

Cairo, Egypt

Novartis Investigative Site

Amman, Jordan

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Oviedo, Principality of Asturias, Spain

Novartis Investigative Site

West Midlands, Birmingham, United Kingdom

Novartis Investigative Site

London, United Kingdom

Novartis Investigative Site

London, United Kingdom

Novartis Investigative Site

London, United Kingdom

Key Dates

Start Date

July 1, 2011

Primary Completion Date

October 1, 2015

Completion Date

October 1, 2015

Last Updated

February 2, 2016

Enrollment

120

ACTUAL participants

Conditions

Transfusional Hemosiderosis

Interventions

deferasirox

DRUG